Daniel Desrivieres
Optometrist · Orange, NJNPI 1619041506
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 28.6% of the total. Among optometrist clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $61.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sight Sciences, Inc.$1K
- Bausch & Lomb Americas Inc.$726
- Synergeyes, Inc.$521
- Dompe US, Inc.$412
- Aerie Pharmaceuticals, Inc.$289
- plus $2K from 16 others
What the payments were for
- Food & beverage$6,41099%
- Entertainment$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 52 | $1,844 |
| Sight Sciences, Inc. | 9 | $1,121 |
| Bausch & Lomb Americas Inc. | 7 | $726 |
| Synergeyes, Inc. | 1 | $521 |
| Dompe US, Inc. | 4 | $412 |
| Aerie Pharmaceuticals, Inc. | 5 | $289 |
| Glaukos Corporation | 2 | $260 |
| Eyevance Pharmaceuticals LLC | 1 | $150 |
| Biotissue Holdings Inc. | 2 | $128 |
| Sun Pharmaceutical Industries Inc. | 1 | $106 |
| Mallinckrodt Hospital Products Inc. | 1 | $106 |
| Oyster Point Pharma, Inc. | 2 | $105 |
| Visioneering Technologies, Inc. | 1 | $104 |
| Sanofi | 1 | $103 |
| Tarsus Pharmaceuticals, Inc. | 1 | $98 |
| Alcon | 2 | $79 |
| LKC Technologies, Inc. | 1 | $59 |
| Amgen | 1 | $52 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $50 |
| Samsara Vision | 1 | $50 |
| Novartis | 4 | $49 |
| Optos, Inc. | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$750
- DURYSTA$613
- Duette Contact Lenses$521
- LUMIGAN$500
- MIEBO$490
- XIIDRA$490
- Oxervate$350
- COMBIGAN$250
- Rocklatan$249
- Rhopressa$249
- OMNI$233
- Flarex$150
- TearCare SmartLid$137
- TEARCARE(TM) (2.2) SYSTEM KIT$137
- ALPHAGAN P$125
- RESTASIS$123
- VYZULTA$120
- CEQUA$106
- ACTHAR$106
- FABRAZYME$103
How this compares
$6,447 in reported general payments places this provider in the 95th percentile of 1,357 optometrist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 53 | $58,417 |
| LumiganBimatoprost | 78 | $37,527 |
| VyzultaLatanoprostene Bunod | 16 | $7,786 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 34 | $7,731 |
| Cyclosporine | 14 | $5,950 |
| Latanoprost | 595 | $4,011 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 267 | $3,373 |
| Travoprost | 19 | $2,531 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $1,367 |
| Brimonidine Tartrate | 165 | $1,118 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 30 | $1,067 |
| Timolol Maleate | 119 | $852 |
| ErythromycinErythromycin Base | 64 | $678 |
| Dorzolamide Hcl | 41 | $612 |
| Acetazolamide | 21 | $497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $1,844 | $95,944131 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $726 | $7,78616 claims |
| AlconSimbrinza | $79 | $7,73134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 optometrist providers in New Jersey.
Other optometrist in Orange
- Kerry GelbWoodbridge$264K
- Rodolfo RodriguezNorth Bergen$244K
- Steven SorkinFairfield$146K
- Paul VaccarellaRockaway$99K
- Ada NohCinnaminson$74K
- Melanne RosettaIselin$66K
- Frank BuccieroSpringfield$57K
- Victoria DzurinkoDeptford$47K
- Michael McAleeseHowell$33K
- Gary RochaParamus$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.